



ActualEyes Inc. announces implementing financing during June to September, 2019 by a third-party allocation of new shares to “Drug Discovery Gateway Investment Limited Partnership” (organized by Whiz Partners Inc.), “Mitsubishi UFJ Life Science II, Limited Partnership” (organized by Mitsubishi UFJ Capital Co., Ltd.), Japan Science and Technology Agency (JST) and “Kyogin Shining Future Support Fund II Investment Limited Partnership” (organized by Kyogin Lease & Capital Co., Ltd.).

With this funding ActualEyes will accelerate the research and development of cell-therapy and pharmacological treatments for corneal endothelial diseases.